GSK PLC ADS EACH news, videos and press releases
For more news please use our advanced search feature.
GSK PLC ADS EACH - More news...
GSK PLC ADS EACH - More news...
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
- ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
- INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
- Shingrix approved in the US for prevention of shingles in immunocompromised adults
- Elliott Publishes Letter on GlaxoSmithKline
- Elliott Publishes Letter on GlaxoSmithKline
- Thinking about trading options or stock in Xpeng, GlaxoSmithKline, Nutanix, Roku, or AMC?
- FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
- Thinking about buying stock in Dell Technologies, American Eagle Outfitters, Wrap Technologies, PPD Inc, or GlaxoSmithKline?
- Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
- Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
- TUMS® Kicks Off $55,000 #TUMSBingoSweepstakes for the BIG GAME
- FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
- FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)
- FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US
- Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin)
- Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval
- GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma
- FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
- FDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the United States
